US Patent 9968659 Liraglutide in cardiovascular conditions
Patent 9968659 was granted and assigned to Novo Nordisk on May, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 9 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+107 characters)
Article
Patent abstract
The present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09968659 Liraglutide in cardiovascular conditions US Patent 9968659 Liraglutide in cardiovascular conditions
Infobox
Patent Number
0996865900
Patent Number
996865900
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
099686590
Date of Patent
May 15, 2018
0Patent Application Number
154016510
Date Filed
January 9, 2017
0Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
099686590
Date of Patent
May 15, 2018
0Patent Application Number
154016510
Date Filed
January 9, 2017
0Patent Primary Examiner
Edits on 20 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09968659 Liraglutide in cardiovascular conditions
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09968659
Date of patent
May 15, 2018
Patent application number
15401651
Date Filed
January 9, 2017
Patent primary examiner
Find more entities like US Patent 9968659 Liraglutide in cardiovascular conditions
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.